Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
A randomized, multidisciplinary study, Phase II-III clinical trial.The study is opened to the
incorporation of other centers that would increase the power of the obtained results . Our
hypothesis considers that using Hyperthermic Intra-abdominal Chemotherapy,HIPEC, with
gemcitabine after cytoreductive surgery ,will decrease tumor progression of pancreatic cancer
by reducing the neoplastic volume and subpopulation of pancreatic cancer stem cells,
improving the survival of patients with pancreatic cancer, and decreasing the recurrence of
the disease